Dronedarone is the class III anti arrhythmatic drug of benzofuron derivative having high lipophilicity and less aqueous solubility and less dissolution rate. The bioavailability (absolute) of the drug in absence of food is reported as low which is nearly 4%. The presence of fatty meal increases the bioavailability of dronedarone to nearly about 15%. Thus in this research work a solid dispersion formulation is tried which enhances the oral bioavailability and Dissolution profile of the poorly aqueous soluble Dronedarone HCl.